Please login to the form below

Not currently logged in
Email:
Password:

UCB admits Keppra misbranding offence

UCB is to pay $34m after admitting to off-label marketing of its epilepsy drug Keppra as a treatment for migraine

UCB has agreed to pay $34.4m to settle a dispute with the US Department of Justice regarding off-label marketing of its epilepsy drug Keppra.

The Belgian company's US subsidiary pleaded guilty to a single misdemeanour violation and entered into a separate civil settlement agreement to resolve allegations relating to misbranding of Keppra (levetiracetam) as a migraine treatment.

Greg Duncan, UCB's president for North American operations, said: "We have worked diligently over the years to enhance our compliance programme and we continue to evolve our compliance efforts to meet the changing demands of the regulatory environment in which we operate. We are pleased to have resolved this matter."

The events occurred more than six years ago, and UCB said it cooperated fully with the US authorities since learning of the investigation in 2008. It also signed a five-year corporate integrity agreement with the US Department of Health and Human Services.

13th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Menopause-thumbnail.png
Breaking the silence: It’s time to talk about the menopause
Using findings from our latest opinion poll, Vicki Newlove outlines why the hidden landscape of menopause may finally be starting to change....
Committing time to making meaningful connections - top 5 tips
Read the second blog of the series looking at key barriers to effective patient engagement in pharma...
News:
Senior Analytics Specialist joins Research Partnership...